Search results
Page 1 of 2
Your search for Remdesivir returned 11 results
Ligand: remdesivir
INN: remdesivir
Comments: Remdesivir (GS-5734) is a nucleotide analogue drug that was developed by Gilead Sciences for antiviral
Clinical use: Remdesivir (GS-5734) must be administered by intravenous (i.v.) infusion. Remdesivir progressed to Phase 2 evaluation
Mechanism of action: Remdesivir is a phosphoramidate adenosine nucleotide analogue that blocks viral RNA-dependent RNA polymerase (RdRp
Bioactivity comments: Remdesivir (GS-5734) inhibits SARS-CoV and MERS-CoV replication in multiple in vitro systems
Comments: Remdesivir (GS-5734) is a nucleotide analogue drug that was developed by Gilead Sciences for antiviral
Clinical use: Remdesivir (GS-5734) must be administered by intravenous (i.v.) infusion. Remdesivir progressed to Phase 2 evaluation
Mechanism of action: Remdesivir is a phosphoramidate adenosine nucleotide analogue that blocks viral RNA-dependent RNA polymerase (RdRp
Bioactivity comments: Remdesivir (GS-5734) inhibits SARS-CoV and MERS-CoV replication in multiple in vitro systems
Ligand: remdesivir triphosphate
Comments: Remdesivir triphosphate (GS-443902) is a metabolite of . It is formed by replacement of the 5'-hydroxyl
Ligand: GS-621763
Comments: remdesivir. Like its parent, this prodrug results in inhibition of viral RNA-dependent RNA polymerase
Bioactivity comments: EC50 of 125 nM . In the same assay system remdesivir's EC50 was 37 nM.
Bioactivity comments: EC50 of 125 nM . In the same assay system remdesivir's EC50 was 37 nM.
Ligand: GS-441524
Comments: remdesivir. GS-441524 potently inhibits SARS-CoV-2 replication in in vitro and in vivoinfection
Bioactivity comments: remdesivir (IC50 1.35 muM) . However the opposite is true in Calu-3 and Caco-2 cells
Bioactivity comments: remdesivir (IC50 1.35 muM) . However the opposite is true in Calu-3 and Caco-2 cells
Target:
CoV RNA-dependent RNA polymerase (Coronavirus (CoV) proteins)
Comment: remdesivir. Although RdRp (nsp12) is strictly a component of the SARS-CoV-2 replicase polyprotein
3D structure - description: nsp7-nsp8 complex bound to the template-primer RNA and triphosphate form of Remdesivir(RTP)
3D structure - description: nsp7-nsp8 complex bound to the template-primer RNA and triphosphate form of Remdesivir(RTP)
Ligand: molnupiravir
Bioactivity comments: remdesivir and EIDD-2801 is that while remdesivir needs to be administered intravenously within a medical
Ligand: clofazimine
Comments: remdesivir. Based on this evidence it is planned to progress clofazimine + remdesivir directly into Phase
Ligand: lufotrelvir
Bioactivity comments: clades from clinical isolates in A549+ACE2 cells, and was statistically more potent than remdesivir .
Target:
dihydroorotate dehydrogenase (quinone) (Nucleoside synthesis and metabolism, 1.-.-.- Oxidoreductases)
Comment: remdesivir) have demonstrated synergistic/additive antiviral activity in mice . PTC Therapeutics are taking their DHODH inhibitor
Target:
CoV Replicase polyprotein 1ab (Coronavirus (CoV) proteins)
Comment: remdesivir, tenofovir and ribavirin . It has a zinc-binding domain in its N-terminus and its activity
Target search page 
Ligand search page
Pharmacology search page
